Greif Bros. Corp (GEF) 49.36 $GEF Greif Has Returned

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Greif Bros. Corp (GEF) 49.36 $GEF

Greif Has Returned 82.0% Since SmarTrend Recommendation (GEF)
Comtex SmarTrend(R) - Fri Sep 23, 12:40PM CDT
SmarTrend identified an Uptrend for Greif (NYSE:GEF) on March 3rd, 2016 at $27.13. In approximately 7 months, Greif has returned 81.97% as of today's recent price of $49.36.
GEF: 49.36 (-0.21)

Zacks.com featured highlights: Tilly's, Francesca's Holdings, Greif, Domtar and Finisar
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:30AM CDT
Zacks.com featured highlights: Tilly's, Francesca's Holdings, Greif, Domtar and Finisar
FNSR: 29.22 (-0.11), TLYS: 9.55 (+0.05), UFS: 36.97 (-0.53), FRAN: 15.13 (-0.06), GEF: 49.36 (-0.21)

5 Stocks with Upgraded Broker Ratings Worth Betting On
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 8:40AM CDT
By following broker rating upgrades, you can easily find attractive stocks. Buy you must take into consideration a few other factors before adding a stock to your investment portfolio. This way you can ensure steady returns.
TLYS: 9.55 (+0.05), FNSR: 29.22 (-0.11), UFS: 36.97 (-0.53), FRAN: 15.13 (-0.06), GEF: 49.36 (-0.21)

Zacks.com featured highlights: Greif, Stoneridge and ARRIS International
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 8:30AM CDT
Zacks.com featured highlights: Greif, Stoneridge and ARRIS International
SRI: 18.88 (-0.14), ARRS: 28.61 (-0.71), GEF: 49.36 (-0.21)

This 'New Highs' Screen is Crushing the Market This Year
Kevin Matras - ZACKS - Tue Sep 20, 2:13PM CDT
This 'New Highs' Screen is Crushing the Market This Year
SRI: 18.88 (-0.14), ARRS: 28.61 (-0.71), GEF: 49.36 (-0.21)

Global Transit Packaging Market Growth of 4.45% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Greif, Mondi, Pratt Industries - Research and Markets
BusinessWire - Fri Sep 16, 3:20AM CDT
Research and Markets has announced the addition of the "Global Transit Packaging Market 2016-2020" report to their offering.
GEF: 49.36 (-0.21)

Greif Up 75.2% Since SmarTrend Uptrend Call (GEF)
Comtex SmarTrend(R) - Fri Sep 16, 12:11AM CDT
SmarTrend identified an Uptrend for Greif (NYSE:GEF) on March 3rd, 2016 at $27.13. In approximately 7 months, Greif has returned 75.15% as of today's recent price of $47.51.
GEF: 49.36 (-0.21)

Is Greif (GEF) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Wed Sep 14, 9:19AM CDT
Greif (GEF) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
GEF: 49.36 (-0.21)

Is it the Right Time to Add Greif (GEF) to Your Portfolio?
Zacks Equity Research - Zacks Investment Research - Wed Sep 14, 9:08AM CDT
On Sep 13, we issued an updated research report on leading global producer of industrial packaging products, Greif, Inc. (GEF).
BERY: 45.81 (+0.19), GEF: 49.36 (-0.21), DXPE: 25.23 (-0.55), PKG: 82.29 (+1.65)

Zacks.com featured highlights: Greif, Tilly's and Urban Outfitters
Zacks Equity Research - Zacks Investment Research - Wed Sep 14, 8:30AM CDT
Zacks.com featured highlights: Greif, Tilly’s and Urban Outfitters
URBN: 35.66 (-0.07), TLYS: 9.55 (+0.05), GEF: 49.36 (-0.21)

Explosive Returns with the Filtered Zacks Rank 5 Strategy
Kevin Matras - ZACKS - Tue Sep 13, 1:05PM CDT
Explosive Returns with the Filtered Zacks Rank 5 Strategy
TLYS: 9.55 (+0.05), URBN: 35.66 (-0.07), GEF: 49.36 (-0.21)

Is Greif (GEF) Stock A Great Combo of Value and Growth?
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:55AM CDT
Greif (GEF) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
GEF: 49.36 (-0.21)

Sonoco Europe Investment to Aid Production, Energy Efficiency
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:31AM CDT
Sonoco (SON) has expanded its production sites for injection-molded rigid plastic packaging in Zwenkau by investing around 8 million euros and adding 25 new employees.
BERY: 45.81 (+0.19), SON: 52.89 (-0.61), GEF: 49.36 (-0.21), PKG: 82.29 (+1.65)

Greif Shares Up 81.1% Since SmarTrend's Buy Recommendation (GEF)
Comtex SmarTrend(R) - Thu Sep 08, 12:40PM CDT
SmarTrend identified an Uptrend for Greif (NYSE:GEF) on March 3rd, 2016 at $27.13. In approximately 6 months, Greif has returned 81.05% as of today's recent price of $49.11.
GEF: 49.36 (-0.21)

3 Reasons Momentum Stock Investors Will Love Greif, Inc. (GEF)
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 7:32AM CDT
Greif, Inc. is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
GEF: 49.36 (-0.21)

Upgrade Alert for Greif (GEF)
Comtex SmarTrend(R) - Wed Sep 07, 3:03AM CDT
Greif (NYSE:GEF) was upgraded from Neutral to Buy at BofA/Merrill today. The stock closed yesterday at $47.22 on volume of 336,000 shares, above average daily volume of 298,000. Greif (NYSE:GEF) is currently priced 19.0% above its average consensus analyst price target of $38.25. Greif shares have support at the 50-day moving average (MA) of $31.65 and additional support at the 200-day MA of $31.25.
GEF: 49.36 (-0.21)

Greif (GEF) in Focus: Stock Moves 6.3% Higher in Session
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:35AM CDT
Greif, Inc. (GEF) was a big mover last session, as the company saw its shares rise over 5% on the day.
GEF: 49.36 (-0.21), ASTE: 58.05 (-1.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 0

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 158

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 30

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 119

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 18

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading